Get the Stockscreener App
50.44
0.04%
-0.02
After Hours:
50.44
Moonlake Immunotherapeutics stock is traded at $50.44, with a volume of 836.55K.
It is down -0.04% in the last 24 hours and up +6.86% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$50.46
Open:
$50.63
24h Volume:
836.55K
Relative Volume:
1.59
Market Cap:
$3.20B
Revenue:
-
Net Income/Loss:
$-145.21M
P/E Ratio:
-21.93
EPS:
-2.3
Net Cash Flow:
$-140.12M
1W Performance:
-8.34%
1M Performance:
+6.86%
6M Performance:
+9.68%
1Y Performance:
+21.10%
1-Day Range:
$49.46
$51.59
1-Week Range:
$46.12
$55.91
52-Week Range:
$31.42
$58.26
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
50.44 | 3.20B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
Phase 3 Trials Accelerate MoonLake Advances for Immunologic Disease Treatment - Insider Monkey
Pattern recognition hints at MoonLake Immunotherapeutics upsideReal-Time Analysis With Entry Targets In Progress - metal.it
MoonLake Immunotherapeutics Inches Toward Key Resistance — Will It BreakEntry Plan for Oversold Reversal Stocks Released - metal.it
Is Now a Good Time to Reenter MoonLake ImmunotherapeuticsSwing Trade Entry With Volume Triggers Released - metal.it
Published on: 2025-07-29 20:29:47 - beatles.ru
MoonLake Immunotherapeutics Company’s Quarterly Earnings Growth: What the Numbers SayWealth Building Stock Market Ideas Based on Momentum - metal.it
Promising Outlook for MoonLake Immunotherapeutics: Buy Rating Backed by Strong Position in Hidradenitis Suppurativa Treatment - TipRanks
What does MLTX's flat EPS in 2024 suggest for investors? - AInvest
Does MoonLake Immunotherapeutics stock perform well during market downturnsStock Market Data Feed For Consistent Profits - jammulinksnews.com
Published on: 2025-07-29 08:56:36 - metal.it
Published on: 2025-07-29 07:59:51 - metal.it
Published on: 2025-07-29 06:35:51 - metal.it
What institutional investors are buying MoonLake Immunotherapeutics stockFast-track wealth growth - jammulinksnews.com
Is MoonLake Immunotherapeutics stock overvalued or undervaluedTake advantage of unprecedented market momentum - jammulinksnews.com
How does MoonLake Immunotherapeutics generate profit in a changing economyFree Stock Market Trend Analysis - jammulinksnews.com
How strong is MoonLake Immunotherapeutics company’s balance sheetAchieve explosive financial results today - jammulinksnews.com
How does MoonLake Immunotherapeutics compare to its industry peersInvest smarter with advanced market data - jammulinksnews.com
What catalysts could drive MoonLake Immunotherapeutics stock higher in 2025Invest confidently with professional advice - jammulinksnews.com
What are MoonLake Immunotherapeutics company’s key revenue driversBuild a diversified portfolio for stability - jammulinksnews.com
Does MoonLake Immunotherapeutics (NASDAQ:MLTX) Have A Healthy Balance Sheet? - 富途牛牛
What analysts say about MoonLake Immunotherapeutics stockMarket-leading profit generation - Autocar Professional
MoonLake Immunotherapeutics Stock Analysis and ForecastUnbelievable profit margins - PrintWeekIndia
Is MoonLake Immunotherapeutics a good long term investmentBreakthrough stock performance - jammulinksnews.com
Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal - insights.citeline.com
MoonLake Immunotherapeutics: Promising Phase 3 Trials and Market Potential for Sonelokimab - TipRanks
What drives MoonLake Immunotherapeutics stock priceExplosive capital gains - jammulinksnews.com
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):